news
Exploring the role of class IIa HDACs in inflammatory diseases
The pharmacological inhibition of class IIa HDACs could be a therapeutic approach for addressing Th17-related inflammatory and autoimmune diseases.
List view / Grid view
Targets
article
Overcoming the complexity of free energy perturbation calculations
In this article, Dr Robert Scoffin, Chairman and CEO at Cresset, explores FEP and its current challenges, and outlines how continuous advancements and strategic approaches are helping to drive the adoption of FEP methods in drug discovery.
news
The effect of ovarian stimulation on IVF outcomes
In mouse models, the differences between oocytes collected by natural or stimulated approaches were investigated.
news
Targeting RAS to overcome FLT3 AML drug resistance
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
news
Mitochondrial depletion results in abnormal protein accumulation
Researchers find the mechanism which may underly the onset and progression of age-related neurodegenerative diseases.
article
Developing the next generation of antibody drug conjugates
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.
news
Evaluating the anti-obesity effects of tocotrienols
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
news
Developing precision medicine for gestational diabetes
Researchers have identified that gestational diabetes is associated with a deficit in placental expression of IGFBP1.
news
Lamotrigine found to prevent NF1 brain tumour growth in mice
The new findings could result in a clinical trial to assess whether a one-year course of treatment could stop brain tumours.
article
Pioneering the advancement of pre-targeted radioimmunotherapies
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.
news
M6A modification is crucial for HIV-1 survival
The discovery of three m6A modifications and their exact locations could lead to the development of drugs that inhibit viral RNA and protein production.
news
Elevated TMAO levels predict future risk of CKD
Elevated levels of trimethylamine N-oxide levels were a stronger indicator of CKD risk than the well-known risk factors.
article
Identifying vascular disease associations
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
news
KCNJ2 inhibition: a therapeutic target for traumatic brain injury
Using cortical organoids, researchers discovered that targeting KCNJ2 could reduce nerve cell death after TBI.
news
Atlas of the human ovary offers huge potential for new treatments
Single-cell RNA sequencing of ovaries resulted in the identification of four major cell types and four immune cell subtypes.